Ocular Therapeutix (OCUL) Other Non-Current Liabilities (2013 - 2026)
Ocular Therapeutix (OCUL) posted quarterly Other Non-Current Liabilities of $10.9 million for Q2 2026, down 22.2% year-over-year from $14.0 million in Q2 2025, and down 9.62% on a QoQ basis from $12.1 million in Q1 2026.
Ocular Therapeutix (OCUL) Other Non-Current Liabilities (2013 - 2026) Analysis & Trends
Ocular Therapeutix has reported Other Non-Current Liabilities for 11 years, with the latest figure at $10.9 million in Q2 2026.
- Other Non-Current Liabilities for Q2 2026 came in at $10.9 million, down 22.2% year-over-year; the trailing twelve-month figure through Jun 2026 was $10.9 million (down 22.2% YoY), and the FY2025 annual result was $13.9 million, up 4.96% from the prior year.
- Other Non-Current Liabilities eased to $10.9 million in Q2 2026, from $12.1 million in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $30.0 million in Q4 2023 and troughed at $6.4 million in Q4 2022.
- A 5-year average of $15.0 million and a median of $13.5 million in 2024 frame the typical range for Other Non-Current Liabilities.
- The widest annual swing landed in 2022, when Other Non-Current Liabilities sank 82.54%; it then soared 372.16% in 2023.
- A 5-year view of Other Non-Current Liabilities shows it stood at $6.4 million in 2022, then soared by 372.16% to $30.0 million in 2023, then tumbled by 55.83% to $13.2 million in 2024, then gained by 4.96% to $13.9 million in 2025, then decreased by 21.53% to $10.9 million in 2026.
- Per Business Quant data, the three most recent Other Non-Current Liabilities figures were $10.9 million in Q2 2026, $12.1 million in Q1 2026, and $13.9 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Ocular Therapeutix | 2.20 Bn | 2.20 Bn | 11.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.91 Mn |
| Mar 31, 2026 | 909,000.00 |
| Dec 31, 2025 | 13.90 Mn |
| Sep 30, 2025 | 14.96 Mn |
| Jun 30, 2025 | 148,000.00 |
| Mar 31, 2025 | 13.85 Mn |
| Dec 31, 2024 | 141,000.00 |
| Sep 30, 2024 | 117,000.00 |
| Jun 30, 2024 | 114,000.00 |
| Mar 31, 2024 | 19.62 Mn |
| Dec 31, 2023 | 29.99 Mn |
| Sep 30, 2023 | 11.38 Mn |
| Jun 30, 2023 | 11.78 Mn |
| Mar 31, 2023 | 100,000.00 |
| Dec 31, 2022 | 93,000.00 |
| Sep 30, 2022 | 11.59 Mn |
| Jun 30, 2022 | 10.46 Mn |
| Mar 31, 2022 | 13.23 Mn |
| Dec 31, 2021 | 20.19 Mn |
| Sep 30, 2021 | 36.06 Mn |